Literature DB >> 22435457

Factors associated with a strictly undetectable viral load in HIV-1-infected patients.

G Martin-Blondel1, K Sauné, V Vu Hai, B Marchou, P Delobel, J Izopet, L Cuzin, P Massip.   

Abstract

OBJECTIVES: The aim of the study was to identify factors associated with a strictly undetectable viral load (VL) using a routine sensitive real-time polymerase chain reaction (RT-PCR) technology.
METHODS: From a large prospective cohort, 1392 patients with a VL<50 HIV-1 RNA copies/mL while receiving a three-drug suppressive regimen for at least 1 year were included in a cross-sectional analysis. Patients were classified into three groups and compared by univariate and multivariate analysis: 479 patients with a strictly undetectable VL (group 1; 34%), 617 patients with detectable VL below the threshold of 20 copies/mL (group 2; 44%), and 296 patients with a VL of 20-50 copies/mL (group 3; 12%).
RESULTS: Comparing groups 1 and 2, VL zenith<5 log(10) copies/mL [odds ratio (OR) 1.51; 95% confidence interval (CI) 1.15-1.99; P=0.003], current CD4 T-cell count<500 cells/μL (OR 1.44; 95% CI 1.08-1.92; P=0.01), and duration of viral suppression<50 copies/mL longer than 2 years (OR 2.32; 95% CI 1.20-4.54; P=0.01) were associated with undetectable VL. Comparing groups 1 and 3, VL zenith<5 log(10) copies/mL (OR 2.48; 95% CI 1.75-3.50; P<0.001), duration of viral suppression<50 copies/mL longer than 1 year (OR 3.33; 95% CI 1.66-6.66; P=0.0006), and nonnucleoside reverse transcriptase inhibitor (NNRTI)-based regimens (OR 1.45; 95% CI 1.03-2.04; P=0.03) were associated with undetectable VL. No individual drug effect was found within NNRTI molecules.
CONCLUSIONS: Longer duration of viral suppression<50 copies/mL, lower viral load zenith and NNRTI-based regimen were independently associated with a strictly undetectable viral load. This routinely used RT-PCR assay may prove to be a valuable tool in further large-scale studies.
© 2012 British HIV Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22435457     DOI: 10.1111/j.1468-1293.2012.01012.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  9 in total

1.  Full Viral Suppression, Low-Level Viremia, and Quantifiable Plasma HIV-RNA at the End of Pregnancy in HIV-Infected Women on Antiretroviral Treatment.

Authors:  Silvia Baroncelli; Maria F Pirillo; Enrica Tamburrini; Giovanni Guaraldi; Carmela Pinnetti; Anna Degli Antoni; Clementina M Galluzzo; Chiara Stentarelli; Roberta Amici; Marco Floridia
Journal:  AIDS Res Hum Retroviruses       Date:  2015-04-08       Impact factor: 2.205

2.  Understanding the Risk of Human Immunodeficiency Virus (HIV) Virologic Failure in the Era of Undetectable Equals Untransmittable.

Authors:  Jayleen K L Gunn; Wendy Patterson; Bridget J Anderson; Carol-Ann Swain
Journal:  AIDS Behav       Date:  2021-01-13

Review 3.  HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.

Authors:  Loredana Sarmati; Gabriella D'Ettorre; Saverio Giuseppe Parisi; Massimo Andreoni
Journal:  Curr HIV Res       Date:  2015       Impact factor: 1.581

4.  True durability: HIV virologic suppression in an urban clinic and implications for timing of intensive adherence efforts and viral load monitoring.

Authors:  Debra A Benator; Angelo Elmi; Manuel D Rodriguez; Howard B Gale; Virginia L Kan; Heather J Hoffman; Susan Tramazzo; Karen Hall; Angela McKnight; Leah Squires
Journal:  AIDS Behav       Date:  2015-04

5.  Viral blips during suppressive antiretroviral treatment are associated with high baseline HIV-1 RNA levels.

Authors:  Erik Sörstedt; Staffan Nilsson; Anders Blaxhult; Magnus Gisslén; Leo Flamholc; Anders Sönnerborg; Aylin Yilmaz
Journal:  BMC Infect Dis       Date:  2016-06-21       Impact factor: 3.090

6.  INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels.

Authors:  Sidonie Lambert-Niclot; Anders Boyd; Djeneba Fofana; Nadia Valin; Marc Wirden; Jean-Luc Meynard; Romain Palich; Rachid Agher; Marc-Antoine Valantin; Vincent Calvez; Christine Katlama; Pierre-Marie Girard; Anne-Geneviève Marcelin; Laurence Morand-Joubert
Journal:  Open Forum Infect Dis       Date:  2019-04-10       Impact factor: 3.835

Review 7.  Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs.

Authors:  Gilles Darcis; Ben Berkhout; Alexander O Pasternak
Journal:  Viruses       Date:  2020-04-27       Impact factor: 5.048

8.  HIV-1 Drug Resistance Profiles of Low-Level Viremia Patients and Factors Associated With the Treatment Effect of ART-Treated Patients: A Cross-Sectional Study in Jiangsu, China.

Authors:  Defu Yuan; Ying Zhou; Lingen Shi; Yangyang Liu; Jing Lu; Jianshuang Chen; Gengfeng Fu; Bei Wang
Journal:  Front Public Health       Date:  2022-07-14

9.  Factors Associated with Low-Level Viraemia and Virological Failure: Results from the Austrian HIV Cohort Study.

Authors:  Gisela Leierer; Katharina Grabmeier-Pfistershammer; Andrea Steuer; Maria Geit; Mario Sarcletti; Bernhard Haas; Manfred Kanatschnig; Michaela Rappold; Robert Zangerle; Bruno Ledergerber; Ninon Taylor
Journal:  PLoS One       Date:  2015-11-13       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.